Dnaprint Genomics Stock Current Asset

DNAPrint Genomics fundamentals help investors to digest information that contributes to DNAPrint Genomics' financial success or failures. It also enables traders to predict the movement of DNAPrint Stock. The fundamental analysis module provides a way to measure DNAPrint Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DNAPrint Genomics stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

DNAPrint Genomics Company Current Asset Analysis

DNAPrint Genomics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.

Current Asset

 = 

Cash

+

Deposits

+

Liquid Assets

More About Current Asset | All Equity Analysis

Current DNAPrint Genomics Current Asset

    
  1.89 M  
Most of DNAPrint Genomics' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DNAPrint Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
Competition

In accordance with the recently published financial statements, DNAPrint Genomics has a Current Asset of 1.89 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current asset for all United States stocks is notably lower than that of the firm.

DNAPrint Current Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DNAPrint Genomics' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DNAPrint Genomics could also be used in its relative valuation, which is a method of valuing DNAPrint Genomics by comparing valuation metrics of similar companies.
DNAPrint Genomics is currently under evaluation in current asset category among its peers.

DNAPrint Fundamentals

About DNAPrint Genomics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze DNAPrint Genomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DNAPrint Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DNAPrint Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Other Consideration for investing in DNAPrint Stock

If you are still planning to invest in DNAPrint Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the DNAPrint Genomics' history and understand the potential risks before investing.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges